Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2019-05-05 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appendix 3B 11 pages 505.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the number of securities issued, issue price, purpose of the issue, and compliance with ASX listing rules. It includes calculations of placement capacity under ASX rules 7.1 and 7.1A, details about the securities, and warranties given to ASX. The document is a formal announcement related to the issuance of new shares and application for quotation of additional securities on the ASX. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the announcement itself, not just a brief notice or report publication announcement.
2019-05-05 English
GTG receives Nasdaq Capital Deficiency notice 1 pag
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 May 2019 from Genetic Technologies Limited regarding a Nasdaq deficiency notice about the company's stockholders' equity falling below the minimum required amount. It discusses the Nasdaq listing rules, the company's plan to regain compliance, and clarifies that the deficiency notice does not immediately affect the Nasdaq listing or the ASX listing. The document is short (2906 characters) and serves as a regulatory announcement about compliance status rather than a financial report or detailed filing. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention any report being attached or published. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about compliance with listing rules and does not fit other specific categories.
2019-05-02 English
Investor Presentation 28 pages 3.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated May 2019, containing forward-looking statements, corporate overview, product descriptions, research collaborations, intellectual property details, and scientific authority information. It is structured as a slide deck with multiple sections describing the company's business, strategy, partnerships, and product pipeline. There are no financial statements, earnings highlights, or regulatory certifications. The content is clearly aimed at investors or stakeholders to provide an overview of the company's operations and future plans. This matches the characteristics of an Investor Presentation (IP) rather than an Annual Report, Earnings Release, or other regulatory filings. The length (15,000 characters) and detailed content support this classification with high confidence.
2019-05-01 English
Operational Update & Appendix 4C 16 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 31 March 2019.' It contains detailed operational highlights, development pipeline updates, collaboration agreements, market expansion activities, and a financial snapshot including cash flow statements. The presence of substantive financial data and analysis for a specific quarter (Q1 2019) indicates this is a comprehensive interim financial report. The Appendix 4C is a standard quarterly cash flow report required by the ASX, reinforcing the quarterly reporting nature. The document is about 15,000 characters long, which is consistent with a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-04-29 English
Extension of Interim CEO Contract 1 page 541.5KB
Board/Management Information Classification · 95% confidence The document is an ASX Market Announcement dated 16 April 2019 from Genetic Technologies Limited. It announces the extension of the Interim CEO's contract and adjustments to his remuneration. There is no financial data, no detailed report, no regulatory certification, or voting results. The content focuses on management changes and plans for a review of the Board and Management structure. This fits the category of Board/Management Information (MANG). The document length is short (2739 characters), and it is a direct announcement, not a report or presentation. Therefore, the classification is MANG with high confidence.
2019-04-15 English
Lapse of Employee Otpions 10 April 2019 1 page 102.
Transaction in Own Shares Classification · 95% confidence The document is an ASX announcement dated 10 April 2019 regarding the lapse of employee share options. It provides details about the number of options lapsed and the total outstanding options. There is no financial statement, no detailed financial analysis, no management discussion, or any other comprehensive report content. The document is short (2923 characters) and serves as a notification about a specific corporate action related to employee share options. This fits the category of a Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares or related share option activities. It is not an announcement of a report publication, nor a full report itself, nor a regulatory filing or management change. Therefore, the best classification is POS with high confidence.
2019-04-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.